Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leucine enkephalin - Virpax Pharmaceuticals

Next Previous
Drug Profile

Leucine enkephalin - Virpax Pharmaceuticals

Alternative Names: Envelta™; Leucine enkephalin intranasal spray - Virpax Pharmaceuticals; METDoloron; Nanoenabled leucine5 enkephalin; NES-100; NM 0127; NM 127; PES200

Latest Information Update: 28 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanomerics
  • Developer Nanomerics; National Center for Advancing Translational Sciences; University of Exeter; Virpax Pharmaceuticals
  • Class Anxiolytics; Enkephalins; Essential amino acids; Opioid analgesics; Opioid peptides
  • Mechanism of Action Opioid delta receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Pain

Highest Development Phases

  • Preclinical Cancer pain; Pain; Post-traumatic stress disorders
  • No development reported Neuropathic pain

Most Recent Events

  • 21 Nov 2024 Virpax Pharmaceuticals and National Centre for Advancing Translational Sciences extends its research and development agreement for Leucine enkephalin intranasal spray in Pain
  • 15 Nov 2023 Virpax Pharmaceuticals plans a phase-I trial in middle of 2024
  • 18 Sep 2023 PES200 is still in preclinical trials for Post-traumatic stress disorders in Germany (Intranasal)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top